The Transcatheter Tricuspid Valve was successfully implanted in two patients in the United States by the Israeli medical device company Trisol Medical Ltd.
By using a minimally invasive technique, the tricuspid valve was replaced during the procedure, negating the requirement for cardiopulmonary bypass. The tricuspid valve of the heart malfunctions, allowing blood to flow backward into the right upper heart chamber each time the right lower heart chamber contracts in both individuals.
Diese condition ist known als symptomatic tricuspid regurgitation. If the disease is not treated, it could result in heart failure or irregular heartbeat. Each operation was a component of a U.S. Early Feasibility Study with Food and Drug Administration Approval.
An 84-year-old woman underwent the first operation at the Piedmont Heart Institute in Atlanta. Through the patient’s jugular vein, the new valve could be inserted by the medical professionals.
She was released after two days, since the physicians noticed a significant improvement in her condition following the treatment. The operation „marks a major milestone in the management of TR”, according to Piedmont physicians James Stewart, Pradeep Yadav, and Vinod Thourani.
Through a minimally invasive treatment, we were able to cure the patient’s valvular heart disease without the requirement for cardiopulmonary bypass. Within hours of the treatment, the patient was moving around, and her Recuperation went smoothly and quickly.
The treatment was performed on the second patient, a 77-year-old woman with a more serious condition, at the University of Virginia Health System in Charlottesville.
She also underwent tricuspid regurgitation reduction, going from “severe” to „trace”, and was released after two days. „The patient had a gratifying result with virtually eliminating her tricuspid regurgitation, rapid recovery, along with significant and rapid improvement in her symptoms,” said the procedure’s doctor, Scott Lim.
We anticipate investigating the Trisol valve further. The patented valve has a leaflet that is attached by two joints, allowing it to operate as a bi-leaflet valve.
“A transcatheter treatment for severe TR is desperately needed. According to Trisol Chairman Dr. Shimon Eckhouse, the company can play a significant role in this field thanks to its encouraging preliminary clinical evidence.
Ten people have the valve implanted thus far, five of whom took part in an Israeli pilot research. Trisol was established in 2016 and is based in Yokneam, close to Haifa.